CSE (Ceftriaxone+ Sulbactam+ Disodium EDTA) Versus Meropenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: PLEA, a Double-Blind, Randomized Noninferiority Trial

M D Amin Mir, Saransh Chaudhary, Anurag Payasi, Rajeev Sood, Ravimohan S Mavuduru, Mohd Shameem, M D Amin Mir, Saransh Chaudhary, Anurag Payasi, Rajeev Sood, Ravimohan S Mavuduru, Mohd Shameem

Abstract

Background: CSE is a novel combination of ceftriaxone, sulbactam and disodium EDTA with activity against multidrug resistant gram-negative pathogens.

Methods: Adult patients aged ≥18 years with a diagnosis of complicated urinary tract infections (cUTI), including acute pyelonephritis (AP), were randomized 1:1 to receive either intravenous CSE (1000mg ceftriaxone/500mg sulbactam/37mg disodium EDTA) every 12h or intravenous meropenem (1000mg) every 8h for up to 14 days. The primary objective was to show the noninferiority of CSE to meropenem at the test-of-cure visit (8-12 days after the end of therapy), with a noninferiority margin of 10 percent.

Results: Of 230 randomized patients, 74/143 and 69/143 were treated with CSE and meropenem respectively. Of these, 98% were ceftriaxone non-susceptible and 83% were ESBL-positive at baseline. Noninferiority of CSE to meropenem was demonstrated for both the US Food and Drug Administration defined co-primary endpoints of (1) symptomatic resolution at test-of-cure: 71/74 (95.9%) patients vs 62/69 (89.9%) [treatment difference, 6%; 95% CI, -2.6% to 16%] and (2) both symptomatic resolution and microbiological eradication at test-of-cure: 70/74 (94.6%) vs 60/69 (87.0%) (treatment difference, 7.6%; 95% CI, -2.0% to 18.4%). Microbiological eradication at test-of-cure (European Medical Agency's primary endpoint) was observed in 70/74 (94.6%) vs 61/69 (88.4%) [treatment difference, 6.2%; 95% CI, -3.2% to 16.6%] patients treated with CSE and meropenem respectively. Safety profile of CSE was consistent with that of ceftriaxone alone.

Conclusions: The results support the use of CSE as a carbapenem-sparing treatment for patients suffering from cUTI/AP caused by resistant gram-negative pathogens.

Clinical trial registration numbers: NCT03477422; CTRI/2013/11/004133.

Keywords: Ceftriaxone-Sulbactam-Disodium EDTA; acute pyelonephritis; complicated urinary tract infections; meropenem.

© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Flowchart representing the patient disposition and study populations.

References

    1. Spellberg B, Blaser M, Guidos RJ, et al. . Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis Off Publ Infect Dis Soc Am 2011; 52(Suppl 5):S397–428.
    1. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 2008; 13 pii:19045.
    1. Laxminarayan R, Duse A, Wattal C, et al. . Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013; 13:1057–98.
    1. Suwantarat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. Antimicrob Resist Infect Control 2016; 5:15.
    1. Gopalakrishnan R, Sureshkumar D. Changing trends in antimicrobial susceptibility and hospital acquired infections over an 8 year period in a tertiary care hospital in relation to introduction of an infection control programme. J Assoc Physicians India 2010; 58(Suppl):25–31.
    1. Patel BV, Patel P, Raval P, et al. . Bacteriological profile and antibiogram of Gram-negative organisms isolated from medical and neurology intensive care unit with special reference to multi-drug resistant organisms. Natl J Med Res 2012; 2:335–8.
    1. Sarojamma V, Ramakrishna V. Prevalence of ESBL-producing Klebsiella pneumoniae isolates in tertiary care hospital. ISRN Microbiol 2011; 2011:318348.
    1. Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009; 73:345–54.
    1. Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis 2015; 15:313.
    1. Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol 2016; 24:862–71.
    1. Czaplewski L, Bax R, Clokie M, et al. . Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis 2016; 16:239–51.
    1. Chaudhary M. Molecular characterization and antimicrobial susceptibility study of Acinetobacter baumannii clinical isolates from Middle East, African and Indian patients. J Proteomics Bioinform 2012; 05. doi: 10.4172/jpb.1000248.
    1. Chaudhary M, Payasi A. Rising antimicrobial resistance of Pseudomonas aeruginosa isolated from clinical specimens in India. J Proteomics Bioinform 2013; 6:5–9. doi: 10.4172/jpb.1000253.
    1. Girotra R, Pyasi A, Chaudhary M, et al. . 1373. Activity of ceftriaxone-sulbactam-EDTA against multi-drug-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae isolates (WHO Critical Priority Pathogens) collected from various hospitals in India. Open Forum Infect Dis 2018; 5:S421.
    1. Chaudhary M. A novel approach to combat acquired multiple resistance in Escherichia coli by using EDTA as efflux pump inhibitor. J Microb Biochem Technol 2012; 04. doi: 10.4172/1948-5948.1000082.
    1. Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 2009; 1794:808–16.
    1. Chaudhary M, Payasi A. Comparative efficacy of antibiotics in biofilms eradication formed by ESBL and non ESBL producing micro-organisms. Int J Drug Dev Res 2012; 4:138–147.
    1. Anurag Payasi MC. Changing trends of commonly used intensive care unit antibiotics due to differential membrane permeability in resistant Escherichia coli collected in EASE programme. J Microb Biochem Technol 2013; 05. doi: 10.4172/1948-5948.1000105.
    1. Payasi A. Inhibition of DNA relaxases by Elores to control spreading of resistant gene through conjugation. Int J Biochem 2013; 108:202–6.
    1. Dwivedi VK, Goswami G, Chaudhary M. Comparative study of CSE 1034 and ceftriaxone in pneumonia induced rat. Clin Exp Pharmacol 2012; 2:108.
    1. Chaudhary M, Krishnaraju V. Acute toxicity studies of fixed dose combination of ceftriaxone+sulbactam+ ethylenediaminetetraacetic acid in Swiss albino mice and Sprague Dawley rats. Int J Pharm Bio Sci 2012; 3:110–22.
    1. Chaudhary M, Sudaroli M, Krishnaraju V. Evaluation of sub-acute toxicity profile of fixed dose combination of ceftriaxone+ sulbactam + ethylenediaminetetraacetic acid in Swiss albino mice and Sprague Dawley rats. J Pharm Res 2011; 4:4511–4514.
    1. Chaudhary M, Payasi A. A randomized, open-label, prospective, multicenter phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections. J Pharm Res 2013; 6:409–14.
    1. Zhong NS, Sun T, Zhuo C, et al. . Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis 2015; 15:161–71.
    1. U.S. Food and Drug Administration. Complicated urinary tract infections: developing drugs for treatment; 2018. Available at: . Accessed January 22, 2019.
    1. Addendum to the Guideline on the Evaluation of Medicinal Products Indicated for Treatment of Bacterial Infections. 24 October 2013 EMA/CHMP/351889/2013Committee for Human Medicinal Products; (CHMP); 2013. Accessed January 22, 2019.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother 2010; 1:100–7.
    1. EUCAST_detection_resistance_mechanisms_V1.pdf Available at: Accessed January 22, 2019.
    1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute; 2013.
    1. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26.
    1. Wagenlehner FM, Umeh O, Steenbergen J, et al. . Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949–56.
    1. Wagenlehner FM, Sobel JD, Newell P, et al. . Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63:754–62.
    1. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. . Once-daily plazomicin for complicated urinary tract infections. N Engl J Med 2019; 380:8.
    1. McCarthy MW, Walsh TJ. Meropenem/vaborbactam fixed combination for the treatment of patients with complicated urinary tract infections. Drugs Today (Barc) 2017; 53:521–30.
    1. Chaudhary M. Prospective study for antimicrobial susceptibility of Escherichia coli isolated from various clinical specimens in India. J Microb Biochem Technol 2012; 04. doi: 10.4172/1948-5948.1000088.
    1. Chaudhary M, Payasi A. Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing Acinetobacter baumanii in Indian intensive care units. J Pharm Res 2013; 7:175–80.
    1. Chaudhary M, Mir MA, Ayub SG; Protocol 06 Group Safety and efficacy of a novel drug Elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study. Braz J Infect Dis 2017; 21:408–17.
    1. Chaudhary M, Ayub SG, Mir MA; Members of Study Group CSE-1034 versus ceftriaxone: efficacy and safety analysis from a randomized, open-labeled phase III study in complicated urinary tract infections. J Glob Infect Dis 2018; 10:188–95.
    1. Low DE, File TM, Eckburg PB, et al. . FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3):iii33–44.
    1. File TM, Low DE, Eckburg PB, et al. . FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66(Suppl 3): iii19–32.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera